Metagenomi Therapeutics MGX Institutional Ownership

Ownership Summary

Metagenomi Therapeutics, Inc. (NASDAQ:MGX) has 48 institutional investors that have filed 13F reports for the period ending March 2026.

• Their combined ownership stood at 17.4% of outstanding shares in March 2026, down from 18.3% in December 2025.
• Their total shares held in MGX increased 26.45% quarter over quarter, and separately, investors owning Metagenomi Therapeutics decreased 40.0% from a year ago.
• Of these 48 funds, 14 grew their exposure to Metagenomi Therapeutics, 15 cut back, and 19 maintained positions.
• In total, institutional investors held 6.53Mn shares in Metagenomi Therapeutics as of March 2026, up by 1.37Mn shares quarter on quarter, and down 3.57Mn shares year over year.
• VANGUARD CAPITAL MANAGEMENT LLC holds the largest position in MGX at 1.06Mn shares as of March 31, 2026, or 2.82% of shares outstanding.
• The largest buyers of Metagenomi Therapeutics for the quarter ending March 2026 were VANGUARD CAPITAL MANAGEMENT LLC (1.06Mn), JACOBS LEVY EQUITY MANAGEMENT, INC (382.15K), VANGUARD FIDUCIARY TRUST CO (170.17K), RENAISSANCE TECHNOLOGIES LLC (159.5K), Wells Fargo & Company/Mn (83.73K).
• Top sellers of MGX stock for the quarter ending March 2026 included JANE STREET GROUP, LLC (282.42K), CITADEL ADVISORS LLC (161.18K), MILLENNIUM MANAGEMENT LLC (65.08K), MARSHALL WACE, LLP (51.62K), Morgan Stanley (32.12K).
• Metagenomi Therapeutics's 10 largest shareholders as of March 2026 include VANGUARD CAPITAL MANAGEMENT LLC (1.06Mn), RENAISSANCE TECHNOLOGIES LLC (787.9K), Catalio Capital Management, LP (528.99K), Peapod Lane Capital LLC (516.76K), TWO SIGMA INVESTMENTS, LP (496.77K), BRIDGEWAY CAPITAL MANAGEMENT, LLC (395.8K), JACOBS LEVY EQUITY MANAGEMENT, INC (382.15K), GEODE CAPITAL MANAGEMENT, LLC (358.2K), PURA VIDA INVESTMENTS, LLC (264.39K), BlackRock, Inc. (230.13K) per Business Quant data.